Evidence map›Paper›PMID 37281307›Full record

ArticleDevelopment, growth & differentiation1996

Integrin VLA-6 (α6β1) is transiently expressed during the development of mouse bone marrow-derived mast cells.

Christine C Fehlner-Gardiner, Shashi Uniyal, Bosco M C Chan

Abstract read
PubMed Publisher
In one paragraph

Article in Development, growth & differentiation, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christine C Fehlner-GardinerTransplantation & Immunobiology Group, The John P. Robarts Research Institute and Department of Microbiology & Immunology, University of Western Ontario, 100 Perth Drive, London, Ontario, Canada N6A 5K8.
Shashi UniyalTransplantation & Immunobiology Group, The John P. Robarts Research Institute and Department of Microbiology & Immunology, University of Western Ontario, 100 Perth Drive, London, Ontario, Canada N6A 5K8.
Bosco M C ChanTransplantation & Immunobiology Group, The John P. Robarts Research Institute and Department of Microbiology & Immunology, University of Western Ontario, 100 Perth Drive, London, Ontario, Canada N6A 5K8.
Western University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study the involvement of VLA-6 (α6β1) integrin, a laminin receptor, was characterized during the course of mouse bone marrow-derived mast cell (BMMC) development. Flow cytometry and immunoprecipitation revealed increases in α6 integrin expression during the first 3 weeks, followed by a decline, such that α6β1 was no longer detectable by week 13. Using RT-PCR, transcripts for α6A but not the α6B isoform were detected. Results from immunoprecipitation and costaining with β1-or β4-specific mAb showed the expression of VLA-6 (α6β1) and not α6β4 heterodimers. Moreover, the ability of BMMC to interact with laminin correlated with the time period of VLA-6 expression. However, only 40% of adhesion to laminin was inhibited by blocking mAb for α6, indicating the involvement of additional laminin receptor(s). This is supported by the immunoprecipitation of VLA-2 integrin, also known to have laminin binding properties. Heterogeneity of VLA-6 expression was also found in connective tissue-type mast cells; thus, VLA-6

Indexed as

integrinsmouse bone marrow-derived mast cellsVLA-6 (α6β1)

Identifiers

PMID37281307
OpenAlexW2081834040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.